{
    "clinical_study": {
        "@rank": "72100", 
        "arm_group": {
            "arm_group_label": "Patient Arm- temsirolimus"
        }, 
        "brief_summary": {
            "textblock": "This is a post marketing surveillance which determines the safety profile of the product to\n      Filipinos.  This is a FDA requirement for registration."
        }, 
        "brief_title": "A Post Marketing Surveillance As Required By Philippine Food And Drug Administration", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Philippine Food and Drug Administration requires that a post marketing surveillance\n      study be conducted nationwide and enroll approximately 3,000 study patients. In cases where\n      the 3,000 patients will not be met, the total sample size can be reduced to 10% of the\n      volume of drug use during the first year of it being marketed. Final sample size will be\n      determined after one year of marketing authorization. The decision to use Torisel must be a\n      joint decision made by the subject and the investigator.\n\n      The investigator must discuss product information with the subject as per usual practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects that will be included in this post marketing surveillance study must be\n             consistent with the approved label indication of Torisel in the Philippines.\n\n          -  As per approved label indication, patients diagnosed with advanced renal cell\n             carcinoma will be the ones eligible to participate in the study.\n\n          -  The decision to prescribe Torisel will necessarily precede and will be independent of\n             the decision to enroll the patient into the study.\n\n          -  Evidence of a personally signed and dated informed consent document indicating that\n             the subject (or a legally acceptable representative) has been informed of all\n             pertinent aspects of the study.\n\n        Exclusion Criteria:\n\n          -  Subjects with conditions that are contraindicated with Torisel based on the approved\n             local product document in the Philippines will be excluded in this study. This\n             condition includes: Patients with bilirubin >1.5 x ULN."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This is a prospective observational, non-interventional study which will evaluate Torisel\n        in Filipino adult subjects. Because the data to be collected will be under routine\n        clinical conditions, subjects who have any of the contraindications specified in the\n        product package insert are to be excluded.  Torisel will be prescribed and administered\n        according to the approved product information of the drug in the Philippines. Pfizer will\n        not provide the drug for this study."
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781442", 
            "org_study_id": "B1771110"
        }, 
        "intervention": {
            "arm_group_label": "Patient Arm- temsirolimus", 
            "description": "The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.\nTreatment will continue until disease progression or unacceptable toxicity.\nThe use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.", 
            "intervention_name": "Temsirolimus", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Metastatic Renal Cell Carcinoma", 
        "lastchanged_date": "April 30, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1771110&StudyName=A%20Post%20Marketing%20Surveillance%20As%20Required%20By%20Philippine%20Food%20And%20Drug%20Administration"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Philippines : Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with Adverse Events [AEs]  and Serious Adverse Events [SAEs]", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781442"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}